Cognition Therapeutics (CGTX) Competitors $0.45 +0.12 (+35.44%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.45 0.00 (-0.44%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. ZURA, ONCY, QNCX, PYXS, BMEA, INCR, ABOS, IMUX, IKNA, and MNOVShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Zura Bio (ZURA), Oncolytics Biotech (ONCY), Quince Therapeutics (QNCX), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Ikena Oncology (IKNA), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Zura Bio Oncolytics Biotech Quince Therapeutics Pyxis Oncology Biomea Fusion InterCure Acumen Pharmaceuticals Immunic Ikena Oncology MediciNova Cognition Therapeutics (NASDAQ:CGTX) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment. Do institutionals and insiders believe in CGTX or ZURA? 43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, CGTX or ZURA? Cognition Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500. Do analysts rate CGTX or ZURA? Cognition Therapeutics currently has a consensus target price of $2.83, indicating a potential upside of 524.08%. Zura Bio has a consensus target price of $14.33, indicating a potential upside of 1,161.74%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Cognition Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is CGTX or ZURA more profitable? Zura Bio's return on equity of -42.84% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -194.42% -115.14% Zura Bio N/A -42.84%-35.22% Does the media refer more to CGTX or ZURA? In the previous week, Cognition Therapeutics had 4 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Cognition Therapeutics and 1 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.71 beat Cognition Therapeutics' score of 0.27 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher valuation & earnings, CGTX or ZURA? Zura Bio is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$33.97M-$0.74-0.61Zura BioN/AN/A-$45.39M-$0.70-1.62 SummaryZura Bio beats Cognition Therapeutics on 9 of the 13 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.11M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio-0.6121.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book1.467.538.035.65Net Income-$33.97M-$55.14M$3.18B$249.15M7 Day Performance51.33%4.61%2.93%3.28%1 Month Performance53.74%0.90%1.72%3.95%1 Year Performance-76.23%5.40%34.39%20.98% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.7851 of 5 stars$0.45+35.4%$2.83+524.1%-76.2%$25.11MN/A-0.6120News CoverageGap UpHigh Trading VolumeZURAZura Bio3.4964 of 5 stars$1.05flat$14.33+1,265.1%-67.5%$71.79MN/A-1.503Positive NewsGap UpONCYOncolytics Biotech1.6833 of 5 stars$0.77+3.0%$4.33+460.6%-12.5%$70.77MN/A-2.6730News CoverageQNCXQuince Therapeutics2.8889 of 5 stars$1.65+6.5%$8.00+384.8%+120.1%$70.48MN/A-1.1960PYXSPyxis Oncology1.2128 of 5 stars$1.10flat$9.00+718.2%-61.6%$68.14M$16.15M-0.6960News CoveragePositive NewsBMEABiomea Fusion2.5548 of 5 stars$1.80-0.6%$21.40+1,088.9%-60.9%$68.01MN/A-0.5150INCRInterCureN/A$1.47-1.3%N/A-36.0%$67.90M$66.28M0.00350Gap UpHigh Trading VolumeABOSAcumen Pharmaceuticals1.2459 of 5 stars$1.16+3.6%$6.33+446.0%-49.6%$67.84MN/A-0.6020Positive NewsIMUXImmunic2.9449 of 5 stars$0.70-0.4%$11.60+1,563.1%-32.5%$67.07MN/A-0.5770Positive NewsIKNAIkena Oncology2.3953 of 5 stars$1.34-1.5%$3.00+123.9%-19.9%$65.63M$9.16M-1.5670Positive NewsMNOVMediciNova1.8359 of 5 stars$1.31-1.5%$7.00+434.4%-10.6%$65.23M$1M-5.7010Gap Down Related Companies and Tools Related Companies Zura Bio Competitors Oncolytics Biotech Competitors Quince Therapeutics Competitors Pyxis Oncology Competitors Biomea Fusion Competitors InterCure Competitors Acumen Pharmaceuticals Competitors Immunic Competitors Ikena Oncology Competitors MediciNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
